Asterias Biotherapeutics Inc (AST) 4.51 $AST Wh
Post# of 273254
Posted On: 09/21/2016 11:09:16 PM
Asterias Biotherapeutics Inc (AST) 4.51 $AST
Why Asterias Biotherapeutics (AST) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 7:31AM CDT
Asterias Biotherapeutics not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
AST: 4.51 (+0.16)
BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
BusinessWire - Thu Sep 15, 3:07PM CDT
BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficacy data from the AST-OPC1 SCiSTAR Phase 1/2a clinical study in patients with complete cervical spinal cord injuries at the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS) on September 14, 2016.
BTX: 3.48 (+0.01), AST: 4.51 (+0.16)
Asterias Biotherapeutics (AST) Catches Eye: Stock Jumps 6%
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 7:35AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares rise 6% on the day.
ANIP: 65.12 (+0.28), AST: 4.51 (+0.16)
Will Asterias Biotherapeutics (AST) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Sep 14, 9:09AM CDT
As of late, it has definitely been a great time to be an investor in Asterias Biotherapeutics, Inc. (AST)
AST: 4.51 (+0.16)
Asterias Biotherapeutics AST-OPC1 Treatment for Spinal Cord Injury Patients Shown to Help Patients Paralyzed from the Neck Down Regain Function in the Arms and Hands
PR Newswire - Wed Sep 14, 9:03AM CDT
The News: Asterias Biotherapeutics, based in Fremont, California, announced today positive interim efficacy data in the Company's ongoing Phase 1/2a clinical study in complete cervical spinal cord injury (loss of both motor function and sensation below the neck) patients. While early in the study, with only 4 of the 5 patients having reached 90 days after dosing, all patients who received 10 million AST-OPC1 cells have shown at least one motor level of improvement (regaining some function in their arms) while 2 of 5 patients achieved two motor levels of improvement (regaining some function in their arms, hands and fingers) on at least one side of their body. Researchers initially thought that results would take 6-12 months to see. The next phase of the study - starting this fall -- will utilize an even higher dose of AST-OPC1 (20 million cells).
AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1
PR Newswire - Wed Sep 14, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today presented positive interim efficacy data from the 10 million cell cohort in the Company's ongoing AST-OPC1 SCiSTAR Phase 1/2a multicenter clinical study in complete cervical spinal cord injury patients. While early in the study, with only 4 of the 5 patients in the cohort having reached 90 days after dosing, all patients have shown at least one motor level of improvement so far and the efficacy target of 2 of 5 patients in the cohort achieving two motor levels of improvement on at least one side of their body has already been achieved. Patient improvements are being measured by the ISNCSCI neurological classification scale widely used to quantify functional status of patients with spinal cord injuries. As suggested by existing research, patients with complete cervical spinal cord injuries that show two motor levels of improvement on at least one side may regain the ability to perform daily activities such as feeding, dressing and bathing.
AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016
PR Newswire - Tue Sep 13, 6:00AM CDT
Asterias Biotherapeutics (NYSE MKT: AST) announced today that Charles Y. Liu, MD, PhD, Director, USC Neurorestoration Center and investigator on the AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients, will participate on the company's conference call on Wednesday, September 14, 2016. Dr. Liu will discuss interim efficacy data observed in patients from the 10 million cell cohort in the ongoing SCiSTAR study.
AST: 4.51 (+0.16)
Asterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September 12, 2016, in Advance of Upcoming Interim Efficacy Data Release from Spinal Cord Injury Trial
PR Newswire - Mon Sep 12, 8:15AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, announced that Steve Cartt, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference today, Monday, September 12, 2016 at 5:05 PM Eastern Time at The Lotte New York Palace Hotel. A live webcast of the presentation will be accessible at http://asteriasbiotherapeutics.com/events-presentations/. An archived presentation will be available for 90 days after the event.
AST: 4.51 (+0.16)
Asterias Biotherapeutics (AST) Soars: Stock Rises by 10.9%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:00AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
ANIP: 65.12 (+0.28), AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients to be Presented at the 55th ISCoS Annual Scientific Meeting
PR Newswire - Wed Sep 07, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth, MD, PhD, Chief Medical Officer, will present interim efficacy data from the 10 million cell cohort in the company's ongoing AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients on Wednesday, September 14, 2016. The presentation will take place during the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS), which is being held in Vienna, Austria, on September 14-16, 2016.
AST: 4.51 (+0.16)
Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
PR Newswire - Wed Aug 31, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee (DMC) has reviewed the safety data from the initial cohort of three patients dosed with 2 million cells, and a subsequent five patients in the second cohort dosed with 10 million cells, and has cleared the company to now begin dosing a third cohort of 5-8 complete cervical injury patients (AIS-A patients) with the highest dose of 20 million cells. Concurrently, the study is also proceeding with enrolling the first cohort of 5-8 sensory incomplete cervical spinal cord injury patients (AIS-B patients), each of whom will be administered 10 million cells.
AST: 4.51 (+0.16)
Don M. Bailey Appointed to OncoCyte Corporation's Board of Directors
GlobeNewswire - Mon Aug 29, 3:15PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today announced the appointment of Don M. Bailey to the Company's Board of Directors. Mr. Bailey will also be making a $750,000 investment in OncoCyte as part of the financing announced today by the Company.
OCX: 4.57 (+0.39), AST: 4.51 (+0.16)
Should You Buy Asterias Biotherapeutics (AST) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:56AM CDT
Asterias Biotherapeutics has earnings coming up pretty soon and events are shaping up quite nicely for its report.
AST: 4.51 (+0.16)
3 Healthcare Stocks Poised to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 10:26AM CDT
in the second quarter, results have managed to outpace expectations so far.
EVOK: 1.89 (+0.01), AST: 4.51 (+0.16), ORPN: 1.83 (+0.04)
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
BusinessWire - Tue Aug 09, 3:18PM CDT
--Deconsolidation Simplifies Financials
OCX: 4.57 (+0.39), BTX: 3.48 (+0.01), AST: 4.51 (+0.16)
Will Q2 Earnings Hold a Surprise for Davita (DVA) Stock?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 9:14AM CDT
DaVita HealthCare Partners Inc. (DVA) is set to report second-quarter 2016 results after the market closes on Aug 8.
DVA: 65.83 (+0.84), ADHD: 4.72 (+0.11), AST: 4.51 (+0.16), ALQA: 0.85 (-0.03)
Asterias Biotherapeutics to Report Second Quarter Results on August 15, 2016
PR Newswire - Mon Aug 01, 6:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 15, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on August 15, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate developments.
AST: 4.51 (+0.16)
ASTERIAS BIOTHERAPEUTICS (AST) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Jun 06, 7:03AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Asterias Biotherapeutics, Inc. (NYSE:AST) ("Asterias Biotherapeutics" or the "Company"
.
AST: 4.51 (+0.16)
Why Asterias Biotherapeutics (AST) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 7:31AM CDT
Asterias Biotherapeutics not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
AST: 4.51 (+0.16)
BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
BusinessWire - Thu Sep 15, 3:07PM CDT
BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficacy data from the AST-OPC1 SCiSTAR Phase 1/2a clinical study in patients with complete cervical spinal cord injuries at the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS) on September 14, 2016.
BTX: 3.48 (+0.01), AST: 4.51 (+0.16)
Asterias Biotherapeutics (AST) Catches Eye: Stock Jumps 6%
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 7:35AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares rise 6% on the day.
ANIP: 65.12 (+0.28), AST: 4.51 (+0.16)
Will Asterias Biotherapeutics (AST) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Sep 14, 9:09AM CDT
As of late, it has definitely been a great time to be an investor in Asterias Biotherapeutics, Inc. (AST)
AST: 4.51 (+0.16)
Asterias Biotherapeutics AST-OPC1 Treatment for Spinal Cord Injury Patients Shown to Help Patients Paralyzed from the Neck Down Regain Function in the Arms and Hands
PR Newswire - Wed Sep 14, 9:03AM CDT
The News: Asterias Biotherapeutics, based in Fremont, California, announced today positive interim efficacy data in the Company's ongoing Phase 1/2a clinical study in complete cervical spinal cord injury (loss of both motor function and sensation below the neck) patients. While early in the study, with only 4 of the 5 patients having reached 90 days after dosing, all patients who received 10 million AST-OPC1 cells have shown at least one motor level of improvement (regaining some function in their arms) while 2 of 5 patients achieved two motor levels of improvement (regaining some function in their arms, hands and fingers) on at least one side of their body. Researchers initially thought that results would take 6-12 months to see. The next phase of the study - starting this fall -- will utilize an even higher dose of AST-OPC1 (20 million cells).
AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1
PR Newswire - Wed Sep 14, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today presented positive interim efficacy data from the 10 million cell cohort in the Company's ongoing AST-OPC1 SCiSTAR Phase 1/2a multicenter clinical study in complete cervical spinal cord injury patients. While early in the study, with only 4 of the 5 patients in the cohort having reached 90 days after dosing, all patients have shown at least one motor level of improvement so far and the efficacy target of 2 of 5 patients in the cohort achieving two motor levels of improvement on at least one side of their body has already been achieved. Patient improvements are being measured by the ISNCSCI neurological classification scale widely used to quantify functional status of patients with spinal cord injuries. As suggested by existing research, patients with complete cervical spinal cord injuries that show two motor levels of improvement on at least one side may regain the ability to perform daily activities such as feeding, dressing and bathing.
AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016
PR Newswire - Tue Sep 13, 6:00AM CDT
Asterias Biotherapeutics (NYSE MKT: AST) announced today that Charles Y. Liu, MD, PhD, Director, USC Neurorestoration Center and investigator on the AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients, will participate on the company's conference call on Wednesday, September 14, 2016. Dr. Liu will discuss interim efficacy data observed in patients from the 10 million cell cohort in the ongoing SCiSTAR study.
AST: 4.51 (+0.16)
Asterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September 12, 2016, in Advance of Upcoming Interim Efficacy Data Release from Spinal Cord Injury Trial
PR Newswire - Mon Sep 12, 8:15AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, announced that Steve Cartt, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference today, Monday, September 12, 2016 at 5:05 PM Eastern Time at The Lotte New York Palace Hotel. A live webcast of the presentation will be accessible at http://asteriasbiotherapeutics.com/events-presentations/. An archived presentation will be available for 90 days after the event.
AST: 4.51 (+0.16)
Asterias Biotherapeutics (AST) Soars: Stock Rises by 10.9%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:00AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
ANIP: 65.12 (+0.28), AST: 4.51 (+0.16)
Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients to be Presented at the 55th ISCoS Annual Scientific Meeting
PR Newswire - Wed Sep 07, 6:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth, MD, PhD, Chief Medical Officer, will present interim efficacy data from the 10 million cell cohort in the company's ongoing AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients on Wednesday, September 14, 2016. The presentation will take place during the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS), which is being held in Vienna, Austria, on September 14-16, 2016.
AST: 4.51 (+0.16)
Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
PR Newswire - Wed Aug 31, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee (DMC) has reviewed the safety data from the initial cohort of three patients dosed with 2 million cells, and a subsequent five patients in the second cohort dosed with 10 million cells, and has cleared the company to now begin dosing a third cohort of 5-8 complete cervical injury patients (AIS-A patients) with the highest dose of 20 million cells. Concurrently, the study is also proceeding with enrolling the first cohort of 5-8 sensory incomplete cervical spinal cord injury patients (AIS-B patients), each of whom will be administered 10 million cells.
AST: 4.51 (+0.16)
Don M. Bailey Appointed to OncoCyte Corporation's Board of Directors
GlobeNewswire - Mon Aug 29, 3:15PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today announced the appointment of Don M. Bailey to the Company's Board of Directors. Mr. Bailey will also be making a $750,000 investment in OncoCyte as part of the financing announced today by the Company.
OCX: 4.57 (+0.39), AST: 4.51 (+0.16)
Should You Buy Asterias Biotherapeutics (AST) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:56AM CDT
Asterias Biotherapeutics has earnings coming up pretty soon and events are shaping up quite nicely for its report.
AST: 4.51 (+0.16)
3 Healthcare Stocks Poised to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 10:26AM CDT
in the second quarter, results have managed to outpace expectations so far.
EVOK: 1.89 (+0.01), AST: 4.51 (+0.16), ORPN: 1.83 (+0.04)
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
BusinessWire - Tue Aug 09, 3:18PM CDT
--Deconsolidation Simplifies Financials
OCX: 4.57 (+0.39), BTX: 3.48 (+0.01), AST: 4.51 (+0.16)
Will Q2 Earnings Hold a Surprise for Davita (DVA) Stock?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 9:14AM CDT
DaVita HealthCare Partners Inc. (DVA) is set to report second-quarter 2016 results after the market closes on Aug 8.
DVA: 65.83 (+0.84), ADHD: 4.72 (+0.11), AST: 4.51 (+0.16), ALQA: 0.85 (-0.03)
Asterias Biotherapeutics to Report Second Quarter Results on August 15, 2016
PR Newswire - Mon Aug 01, 6:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 15, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on August 15, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate developments.
AST: 4.51 (+0.16)
ASTERIAS BIOTHERAPEUTICS (AST) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Jun 06, 7:03AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Asterias Biotherapeutics, Inc. (NYSE:AST) ("Asterias Biotherapeutics" or the "Company"
. AST: 4.51 (+0.16)
(0)
(0)Scroll down for more posts ▼